MX2018010696A - Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas. - Google Patents
Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas.Info
- Publication number
- MX2018010696A MX2018010696A MX2018010696A MX2018010696A MX2018010696A MX 2018010696 A MX2018010696 A MX 2018010696A MX 2018010696 A MX2018010696 A MX 2018010696A MX 2018010696 A MX2018010696 A MX 2018010696A MX 2018010696 A MX2018010696 A MX 2018010696A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- bioactive molecules
- biologically active
- active molecules
- intracellular delivery
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 230000003834 intracellular effect Effects 0.000 title 1
- 230000000975 bioactive effect Effects 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 230000000149 penetrating effect Effects 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101100239628 Danio rerio myca gene Proteins 0.000 abstract 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 abstract 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 101150111214 lin-28 gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/34—Belt retractors, e.g. reels
- B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
- B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/289—Energy-absorption curves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mechanical Engineering (AREA)
- Toxicology (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Las nanopartículas biocompatibles funcionalizadas capaces de penetrar a través de una membrana celular de mamífero y suministrar intracelularmente una pluralidad de moléculas bioactivas para modular una función celular se describen en la presente Las nanopartículas biocompatibles funcionalizadas comprenden: una nanopartícula central que varía en tamaño desde alrededor de hasta alrededor de 50 nm y que tiene un recubrimiento de polímero sobre la misma, una pluralidad de grupos funcionales covalentemente enlazados al recubrimiento de polímero, en donde la pluralidad de moléculas bioactivas se enlazan a la pluralidad de los grupos funcionales, y en donde la pluralidad de moléculas bioactivas incluye al menos un péptido y una proteína, y en donde el péptido es capaz de penetrar a través de la membrana celular de mamífero y entrar en la célula, y en donde la proteína es capaz de proporcionar una nueva funcionalidad dentro de la célula. La proteína puede ser un factor de transcripción seleccionado del grupo que consiste de Oct4, Sox2, Nanog, Lin28, cMyc, y Klf4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550213P | 2011-10-21 | 2011-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010696A true MX2018010696A (es) | 2020-09-02 |
Family
ID=48141479
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002306A MX367656B (es) | 2011-10-21 | 2012-10-22 | Nanopartículas funcionalizadas para suministro intracelular de moléculas biológicamente activas. |
MX2014004778A MX2014004778A (es) | 2011-10-21 | 2012-10-22 | Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas. |
MX2018010696A MX2018010696A (es) | 2011-10-21 | 2014-04-21 | Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002306A MX367656B (es) | 2011-10-21 | 2012-10-22 | Nanopartículas funcionalizadas para suministro intracelular de moléculas biológicamente activas. |
MX2014004778A MX2014004778A (es) | 2011-10-21 | 2012-10-22 | Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9675708B2 (es) |
EP (2) | EP2769217A4 (es) |
JP (3) | JP2014532628A (es) |
KR (3) | KR20200040924A (es) |
CN (2) | CN106822868A (es) |
AU (3) | AU2012325723A1 (es) |
BR (1) | BR112014009753B1 (es) |
CA (2) | CA2938661A1 (es) |
HK (1) | HK1201089A1 (es) |
IN (1) | IN2014DN03224A (es) |
MX (3) | MX367656B (es) |
RU (2) | RU2018135567A (es) |
SG (2) | SG11201401658SA (es) |
WO (1) | WO2013059831A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059831A1 (en) * | 2011-10-21 | 2013-04-25 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
JP6518197B2 (ja) * | 2013-03-01 | 2019-05-22 | ステルス バイオセラピューティックス コープ | バース症候群の予防または治療のための方法及び組成物 |
CN110339339A (zh) | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
WO2015027243A2 (en) * | 2013-08-23 | 2015-02-26 | Rutgers The State University Of New Jersey | Biologically active synthetic nanoparticle constructs and mehtods of use therof |
US11306326B2 (en) | 2013-08-23 | 2022-04-19 | Rutgers, The State University Of New Jersey | Biologically active synthetic nanoparticle constructs and methods of use thereof |
CN106414723A (zh) * | 2014-02-10 | 2017-02-15 | 纳维基因股份有限公司 | 细胞调节纳米组合物及使用方法 |
CN105440112A (zh) * | 2015-12-07 | 2016-03-30 | 国家纳米科学中心 | 多肽-白蛋白偶联药物、其制备方法及应用 |
CN109641007A (zh) * | 2016-06-03 | 2019-04-16 | 斯特姆詹尼克斯公司 | 用功能化纳米颗粒将人类体细胞直接重编程为选定的(预定的)分化细胞 |
US20210154323A1 (en) * | 2016-06-03 | 2021-05-27 | Stemgenics, Inc. | Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use |
US20190233820A1 (en) * | 2016-10-11 | 2019-08-01 | Stemgenics, Inc. | Nanoparticles functionalized with gene editing tools and related methods |
US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
US11701433B2 (en) | 2017-06-05 | 2023-07-18 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
US20200326325A1 (en) | 2019-04-12 | 2020-10-15 | Lisa Diamond | Nanosensor chip with compound nanopores |
CN110642876A (zh) * | 2019-10-10 | 2020-01-03 | 南京市口腔医院 | 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品 |
CN112472685B (zh) * | 2020-12-10 | 2023-03-24 | 哈尔滨工业大学 | 一种杂化中性粒细胞机器人的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379687A (zh) * | 1999-09-14 | 2002-11-13 | 生物医学阿佩则系统有限公司 | 具有生化活性的磁性毫微粒、其制备方法和应用 |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
CN101389314A (zh) * | 2005-03-14 | 2009-03-18 | 得克萨斯大学体系董事会 | 生物活性fus1肽和纳米颗粒-多肽复合物 |
US8338366B2 (en) * | 2005-03-14 | 2012-12-25 | The Board of Regents of the University of the Texas System | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes |
AU2006282042B2 (en) * | 2005-06-17 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
CA2671850A1 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
WO2008083401A1 (en) | 2007-01-02 | 2008-07-10 | University Of Central Florida Research Foundation Inc. | Methods and materials for stimulating proliferation of stem cells |
KR100925689B1 (ko) | 2007-07-25 | 2009-11-10 | 한국생명공학연구원 | 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질 |
US8283344B2 (en) | 2007-09-10 | 2012-10-09 | Merck & Co., Inc. | Method of treating inherited severe neutropenia |
KR100951719B1 (ko) * | 2007-10-02 | 2010-04-07 | 재단법인서울대학교산학협력재단 | 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도 |
EP2227241A1 (en) | 2007-11-30 | 2010-09-15 | Cytomatrix PTY LTD | Methods of inducing pluripotency involving sox2 protein |
AU2009215426B2 (en) * | 2008-02-21 | 2015-06-11 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with C-terminal elements |
CN102272142A (zh) * | 2008-12-23 | 2011-12-07 | 帷幄生物技术公司 | 非遗传修饰性重编程细胞的组合物和方法 |
RU2556376C2 (ru) * | 2009-04-07 | 2015-07-10 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Опосредованная наночастицами доставка сиквенс-специфичных нуклеаз |
WO2013059831A1 (en) * | 2011-10-21 | 2013-04-25 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
-
2012
- 2012-10-22 WO PCT/US2012/061391 patent/WO2013059831A1/en active Application Filing
- 2012-10-22 RU RU2018135567A patent/RU2018135567A/ru not_active Application Discontinuation
- 2012-10-22 CN CN201610644097.9A patent/CN106822868A/zh active Pending
- 2012-10-22 EP EP12842115.3A patent/EP2769217A4/en not_active Withdrawn
- 2012-10-22 MX MX2018002306A patent/MX367656B/es unknown
- 2012-10-22 CN CN201280063870.2A patent/CN104094119A/zh active Pending
- 2012-10-22 IN IN3224DEN2014 patent/IN2014DN03224A/en unknown
- 2012-10-22 JP JP2014537369A patent/JP2014532628A/ja not_active Withdrawn
- 2012-10-22 KR KR1020207010401A patent/KR20200040924A/ko not_active Application Discontinuation
- 2012-10-22 BR BR112014009753-4A patent/BR112014009753B1/pt not_active IP Right Cessation
- 2012-10-22 SG SG11201401658SA patent/SG11201401658SA/en unknown
- 2012-10-22 CA CA2938661A patent/CA2938661A1/en not_active Abandoned
- 2012-10-22 SG SG10201601746TA patent/SG10201601746TA/en unknown
- 2012-10-22 MX MX2014004778A patent/MX2014004778A/es unknown
- 2012-10-22 KR KR1020197018256A patent/KR20190077124A/ko not_active Application Discontinuation
- 2012-10-22 EP EP18160010.7A patent/EP3400956A1/en not_active Withdrawn
- 2012-10-22 KR KR20147010620A patent/KR20150001711A/ko active Application Filing
- 2012-10-22 CA CA2853128A patent/CA2853128C/en active Active
- 2012-10-22 RU RU2014120465/15A patent/RU2014120465A/ru unknown
- 2012-10-22 US US14/353,280 patent/US9675708B2/en active Active - Reinstated
- 2012-10-22 AU AU2012325723A patent/AU2012325723A1/en not_active Abandoned
-
2014
- 2014-04-21 MX MX2018010696A patent/MX2018010696A/es unknown
-
2015
- 2015-02-12 HK HK15101563.8A patent/HK1201089A1/xx unknown
-
2017
- 2017-06-30 JP JP2017128822A patent/JP6560302B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-31 AU AU2018203848A patent/AU2018203848A1/en not_active Abandoned
- 2018-09-03 JP JP2018164676A patent/JP2018184485A/ja active Pending
-
2020
- 2020-08-27 AU AU2020223737A patent/AU2020223737A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2018184485A (ja) | 2018-11-22 |
CN104094119A (zh) | 2014-10-08 |
EP2769217A4 (en) | 2015-06-03 |
KR20190077124A (ko) | 2019-07-02 |
EP3400956A1 (en) | 2018-11-14 |
SG10201601746TA (en) | 2016-04-28 |
MX2014004778A (es) | 2014-10-17 |
RU2018135567A (ru) | 2018-11-15 |
HK1201089A1 (en) | 2015-08-21 |
KR20150001711A (ko) | 2015-01-06 |
BR112014009753B1 (pt) | 2020-09-15 |
JP6560302B2 (ja) | 2019-08-14 |
US20140342004A1 (en) | 2014-11-20 |
AU2018203848A1 (en) | 2018-06-21 |
AU2020223737A1 (en) | 2020-09-17 |
EP2769217A1 (en) | 2014-08-27 |
IN2014DN03224A (es) | 2015-05-22 |
CA2853128A1 (en) | 2013-04-25 |
CA2938661A1 (en) | 2013-04-25 |
US9675708B2 (en) | 2017-06-13 |
RU2014120465A (ru) | 2015-11-27 |
SG11201401658SA (en) | 2014-07-30 |
JP2014532628A (ja) | 2014-12-08 |
CN106822868A (zh) | 2017-06-13 |
BR112014009753A2 (pt) | 2017-04-25 |
JP2017165781A (ja) | 2017-09-21 |
MX367656B (es) | 2019-08-29 |
CA2853128C (en) | 2016-09-27 |
KR20200040924A (ko) | 2020-04-20 |
WO2013059831A1 (en) | 2013-04-25 |
AU2012325723A1 (en) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010696A (es) | Nanoparticulas funcionalizadas para suministro intracelular de moleculas biologicamente activas. | |
JP2014532628A5 (es) | ||
Zhao et al. | A multifunctional, self-healing, self-adhesive, and conductive sodium alginate/poly (vinyl alcohol) composite hydrogel as a flexible strain sensor | |
Li et al. | Construction of biofunctionalized anisotropic hydrogel micropatterns and their effect on Schwann cell behavior in peripheral nerve regeneration | |
Lou et al. | Functional nanofibers and their applications | |
Park et al. | Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair | |
He et al. | Biomimetic asymmetric composite dressing by electrospinning with aligned nanofibrous and micropatterned structures for severe burn wound healing | |
Mathieu et al. | Cytoskeletal and focal adhesion influences on mesenchymal stem cell shape, mechanical properties, and differentiation down osteogenic, adipogenic, and chondrogenic pathways | |
Kim et al. | Adhesive catechol-conjugated hyaluronic acid for biomedical applications: A mini review | |
Rabiee et al. | Green porous benzamide-like nanomembranes for hazardous cations detection, separation, and concentration adjustment | |
WO2017210666A3 (en) | Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use | |
WO2012064697A3 (en) | Materials presenting notch signaling molecules to control cell behavior | |
EP2615105A4 (en) | CELL PERMEABLE PEPTIDE, BIOACTIVE PEPTIDE CONJUGATE, AND USE THEREOF FROM HUMAN CELLS | |
WO2012058673A3 (en) | Enhanced cancer treatment and monitoring using recombinant vectors | |
WO2011115420A3 (en) | Adhesive extracellular matrix mimetic | |
Vannozzi et al. | Novel ultrathin films based on a blend of PEG-b-PCL and PLLA and doped with ZnO nanoparticles | |
Elsadek et al. | Electrospun nanofibers revisited: an update on the emerging applications in nanomedicine | |
WO2012137150A3 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
Baoum et al. | Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery | |
MX2014002062A (es) | Nanoparticulas de peptido y usos de las mismas. | |
Maturavongsadit et al. | Adhesive peptides conjugated PAMAM dendrimer as a coating polymeric material enhancing cell responses | |
Chibh et al. | Recent advances in the fabrication and bio-medical applications of self-assembled dipeptide nanostructures | |
WO2010079496A3 (en) | Tissue regeneration membrane | |
Moon et al. | Fabrication and characterization of neurocompatible ulvan-based layer-by-layer films | |
WO2011130716A3 (en) | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |